

Prostate Cancer Committee meeting

Date: 20/02/2018

Location: NICE – Manchester

Minutes: Final

Committee members present:	
Waqar Shah (WS) (Chair)	Present for all
Abi Ademoyero (AA)	Present for all
Pauline Bagnall (PB)	Present for all
Guy Chetiyawardana (GC)	Present for all
Charles Frost (CF)	Present for all
John Graham (JG)	Present for all
Sadaf Haque (SH)	Present for all
Peter Jenkins (PJ)	Present for all
Howard Kynaston (HK)	Present for all
Sanjeev Madaan (SM)	Present for all
Brian McGlynn (BM)	Present for all
Jon Oxley (JO)	Present from item 4
Jonathan Richenberg (JR)	Present for all
Mark Robinson (MR)	Present for all
Karen Stalbow (KS)	Present for all

In attendance:		
Jean Bennie (JB)	GUT – Technical Analyst	Present for all
Chris Carmona (CC)	GUT – Senior Technical Analyst	Present for all
Fadi Chehadah (FC)	NICE – Health Economist	Present for all
Rupert Franklin (RF)	NICE – Senior Guidelines Commissioning Manager	Present for all
Thomas Jarratt (TJ)	GUT – Technical Analyst	Present for all
Adam O’Keefe (AO)	GUT – Project Manager	Present for all
Gabriel Rogers (GR)	NICE – Technical Adviser (HE)	Present for all
Sue Spiers (SS)	GUT - Associate Director	Present for all

Observer:	
Alice Biggane (AB)	(Present for items 1 – 7)

1. Introductions and guideline committee working

The Chair welcomed the Committee members and attendees to the fourth meeting on Prostate cancer. The Chair introduced TJ as a new Technical Analyst in the Guideline Updates Team who will present at the clinical evidence identified for Review Question 4. The Committee members and attendees introduced themselves. The Chair informed the Committee that no apologies had been received. The Chair explained that JO was absent for items 1-3 at this meeting due to a conflict of interest relevant to the topic being discussed under item 3.

The Chair outlined the objectives of the meeting, which included:

- Presentation on NICE's updated Conflicts of Interest policy
- Presentation of newly identified evidence supporting review questions 5 and 6
- Clinical and Health economics evidence presentation for Review Question 4
- A discussion on potential expert witnesses to be invited to future meetings
- A conversation on the proposed health economic modelling

Minutes of the previous meeting were agreed as an accurate record.

2. Declaration of interests

AO provided a brief presentation on NICE's new policy on Declaring and managing conflicts of interest for the benefit of the Committee. The Chair then invited the Committee to ask any questions before thanking AO for his presentation.

The Chair then asked the Committee members present to declare any new conflicts of interest to have arisen since the last meeting or relevant to the day's agenda. No new conflicts were declared but a number of committee members agreed to confirm further details of conflicts already declared to AO via email.

It was noted that as an author of one of the papers included in the evidence base for Review Question 4, JG could not participate in the drafting of recommendations, though the Chair declared that JG could participate for the presentation and discussion of the evidence and remain in the room throughout.

3. Revisiting of the following review questions:

Review Question 5: What is the most clinically- and cost-effective scheduling of docetaxel added to standard treatment for the treatment of hormone-

sensitive locally-advanced prostate cancer?

Review Question 6: What is the most clinically- and cost-effective scheduling of docetaxel added to standard treatment for the treatment of hormone-sensitive metastatic prostate cancer?

JB presented the Committee with newly identified evidence supporting Review Questions 5 and 6. The Committee reviewed the recommendations drafted at the previous meeting in light of the new evidence and updated them accordingly.

4. Review Question 4: What is the optimal dose and fractionation schedule for people with localised prostate cancer (T1b–T3a N0 M0) who are treated with radical radiotherapy?

JG presented a brief clinical introduction on the topic of radical radiotherapy for the benefit of those present. The Chair thanked JG for his presentation.

TJ presented the clinical evidence identified for Hypofractionation versus conventional fractionation for the Committee’s consideration. The Committee discussed the evidence and agreed to draft recommendations following presentation of the Health economic evidence on the topic.

5. Review Question 4: What is the optimal dose and fractionation schedule for people with localised prostate cancer (T1b–T3a N0 M0) who are treated with radical radiotherapy? Continued

FC presented the Health economic evidence identified for Hypofractionation versus conventional fractionation for the Committee’s consideration. The Committee discussed the evidence they had been presented with and updated one recommendation from the guideline.

JB and FC then presented the Committee with the clinical and Health economic evidence identified for Brachytherapy versus external beam +/- brachytherapy. The Committee discussed the evidence presented and updated one recommendation from the guideline.

6. Expert witness discussion

CC talked to the Committee about possible sources of expert testimony. The Committee discussed trials and possible unpublished relevant data from which there is likely to be relevant information that could inform the update of this guideline. CC agreed to discuss the options further with the NICE team and contact possible sources of data as appropriate.

7. Health Economics Update

GR and FC led a brief discussion on the proposed original Health economics work

being conducted.

8. Next steps

The Chair confirmed the venue, date and time of the next meeting, as detailed below and thanked the Committee and others present for their contribution to the meeting before closing the meeting.

Date of next meeting: 18 April 2018

Location of next meeting: NICE - Manchester